Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 3(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01173575Completed

Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection

Role: collaborator

NCT01516736Phase 3Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Role: collaborator

NCT01735175Phase 3Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®

Role: collaborator

NCT01859637Phase 4Terminated

Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Role: collaborator

All 4 trials loaded